A5018505072- Advanced Breast Cancer Therapies
- Antibiotics Pharmacokinetics and Efficacy
- Analytical Methods in Pharmaceuticals
- Inflammatory mediators and NSAID effects
- Pharmacological Effects of Natural Compounds
- HER2/EGFR in Cancer Research
- Gastrointestinal motility and disorders
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Radiomics and Machine Learning in Medical Imaging
- Medical Imaging Techniques and Applications
- Cancer survivorship and care
- Cancer-related Molecular Pathways
- Systemic Sclerosis and Related Diseases
- Berberine and alkaloids research
- Pharmacological Receptor Mechanisms and Effects
- Helminth infection and control
- Circular RNAs in diseases
- Drug Solubulity and Delivery Systems
- Drug Transport and Resistance Mechanisms
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Receptor Mechanisms and Signaling
- Pharmaceutical studies and practices
- Phytoestrogen effects and research
Istituti di Ricovero e Cura a Carattere Scientifico
2024-2025
Humanitas University
2022-2025
IRCCS Humanitas Research Hospital
2022-2025
Institut Gustave Roussy
2024
Fondazione Humanitas per la Ricerca
2023
Benemérita Universidad Autónoma de Puebla
2001
University of Pavia
2001
University of Bari Aldo Moro
1997
University of Padua
1995
Institute of Neurological Sciences
1993
Aberrant cyclin-dependent kinase 2 (CDK2) activation has been identified as a main resistance mechanism to CDK4/6 inhibition in hormone-receptor positive (HR+) breast cancer. Additionally, consistent preclinical evidence states its crucial role MYC and CCNE1 overexpressed cancer survival, such triple-negative cancers (TNBC), thus representing an appealing relatively unexplored target treatment opportunity. Despite emerging initial results of novel CDK2 inhibitors (CDK2i) activity,...
Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 evaluated, HER2-low was independently associated significantly worse PFS and OS when compared HER2-0 status. Based on our findings, could become a new biomarker this clinical setting.
A double-blind study comparing the efficacy and tolerability of dothiepin with that placebo in treatment primary fibromyalgia syndrome was carried out. Dothiepin shown to improve significantly condition patients there a significant difference between all clinical variables measured. Only mild transient side-effects were reported. Further controlled studies are required define effects on fibromyalgia.
Based on the unprecedented results observed in recent clinical trials, antibody-drug conjugates (ADCs) have revolutionized treatment algorithm of metastatic breast cancer (mBC). The strategy sequencing different ADCs other lines therapy is highly attractive, but proportion patients who undergone such a context published trials still limited, especially for modern ADCs. HER2-positive disease primarily managed with sequence Historically, trastuzumab emtansine (T-DM1) has been most commonly...
The effectiveness of dothiepin (a tricyclic anti-depressant) at a dose 75 mg given orally night was compared with placebo for 4 weeks in alleviating pain 60 patients classical or definite active rheumatoid arthritis. Patients were classified as either ‘depressed’ ‘not depressed’. week before, during and 2 after the study, 600 ibuprofen three times daily to all patients. Compared placebo, produced significant reduction daytime by end treatment period. Hamilton rating scale significantly...
Recently, the impact of patients’ eating habits on both breast cancer (BC) management and inflammation have been proven. Here, we investigated whether inflammatory could correlate with baseline bowel [18]F-fluorodeoxyglucose (FDG) uptake latter, in turn, pathological Complete Response (pCR) to neoadjuvant chemotherapy (NAC). We included stage I–III BC undergoing standard NAC at IRCCS Humanitas Research Hospital, Italy. Patients fulfilled a survey concerning eating/lifestyle behaviors...
Abstract Background Ribociclib is approved for hormone receptor positive (HR+), human epidermal growth factor 2 negative (HER2−) advanced breast cancer (ABC) treatment, in combination with endocrine therapy. Hematological, hepatic, and cardiac adverse events (AEs) emerged from pivotal trials, but little known about cutaneous (CAEs). Patients Methods We report data a retrospective cohort study of all patients HR+/HER2− ABC treated ribociclib at Humanitas Cancer Center between June 2017...
There is very limited data on the safety of switching between CDK4/6i in patients with HR+/HER2- ABC after discontinuing for toxicity. This international retrospective study investigated consecutive treated 2019 and 2023 at two cancer centers, who switched to another firstCDK4/6i unacceptable toxicity without disease progression. Descriptive statistics, Chi-Squared or Fisher's exact test contingency tables factorial ANOVA were applied. The aimed assess feasibility this approach. Of 1413...
Abemaciclib-induced diarrhea is a relevant concern in clinical practice. Postbiotics have emerged as promising option for managing it.
The treatment of early triple-negative breast cancer (eTNBC) has improved patients' prognosis but often leads to adverse events and sequelae affecting quality life (QoL). Pain Neuroscience Education (PNE) is a promising non-pharmacological intervention in this field. Preliminary data have shown the beneficial effect PNE BC survivors. However, there are still gaps knowledge regarding its optimal use eTNBC. To address issue, prospective pilot study will enroll 30 consecutive patients diagnosed...